Turn Therapeutics Inc.
TTRX Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$10.28
KIRA · Stoqly’s AI analyst, in plain words
- Turn Therapeutics Inc. lost $3.2M in fiscal 2025.
Market cap
$306M
P/E
—
Revenue
—
Net income
−$3.2M
Free cash flow
—
Operating margin
—
Turn Therapeutics Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$3.2M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Turn Therapeutics Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 31, 2026
- Legal name
- Turn Therapeutics Inc.
- CIK
- 0002023016
Turn Therapeutics Inc. · TTRX
Results and finances
The last 2 fiscal years. Amounts in USD.
| Fiscal year | FY24 | FY25 |
|---|---|---|
| Sales and profit | ||
| Net income | −$1.8M | −$3.2M |
| Diluted EPS | −$0.07 | −$0.12 |
| Cash | ||
| Cash from operations | −$1.4M | −$2.6M |
| Share count change | — | 4.0% |
| Debt and strength | ||
| Cash and short-term investments | $0.5M | $4.0M |
| Shareholders' equity | −$0.2M | $4.7M |
| Current ratio | 1.6x | 0.9x |
| Returns and quality | ||
| Return on equity | — | −141.7% |
| Return on tangible equity | — | −84.8% |
| Altman Z'' | −35.3 | −9.0 |
Insiders bought, 12 months
$0.1M
2 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Turn Therapeutics Inc. · TTRX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $10.28 a share, the company is worth $306M.
Source: SEC EDGAR XBRL filings (CIK 0002023016). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.